Search results for the GEO ID: GSE11792  |
(Click on the check boxes provided under "Select for analysis", to initiate grouping) |
(Once the selection is made, click on "Add groups" in "Make groups for comparison", to make a group. Scroll down) |
|
GSM ID | GPL ID |
Select for analysis |
Title |
Source name |
Description |
Characteristics |
GSM298370 | GPL571 |
|
Pat 1_skin_baseline
|
skin, no treatment
|
female, 22, Black or African American
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298371 | GPL571 |
|
Pat 1_skin_treated
|
skin, 8 week isotretinoin treatment
|
female, 22, Black or African American
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298372 | GPL571 |
|
Pat 2_skin_baseline
|
skin, no treatment
|
male, 17, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298373 | GPL571 |
|
Pat 2_skin_treated
|
skin, 8 week isotretinoin treatment
|
male, 17, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298374 | GPL571 |
|
Pat 3_skin_baseline
|
skin, no treatment
|
female, 32, Hispanic
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298375 | GPL571 |
|
Pat 3_skin_treated
|
skin, 8 week isotretinoin treatment
|
female, 32, Hispanic
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298376 | GPL571 |
|
Pat 4_skin_baseline
|
skin, no treatment
|
male, 15, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298377 | GPL571 |
|
Pat 4_skin_treated
|
skin, 8 week isotretinoin treatment
|
male, 15, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298378 | GPL571 |
|
Pat 5_skin_baseline
|
skin, no treatment
|
male, 18, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298379 | GPL571 |
|
Pat 5_skin_treated
|
skin, 8 week isotretinoin treatment
|
male, 18, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298380 | GPL571 |
|
Pat 6_skin_baseline
|
skin, no treatment
|
female, 24, Hispanic
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298381 | GPL571 |
|
Pat 6_skin_treated
|
skin, 8 week isotretinoin treatment
|
female, 24, Hispanic
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298382 | GPL571 |
|
Pat 7_skin_baseline
|
skin, no treatment
|
male, 14, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298383 | GPL571 |
|
Pat 7_skin_treated
|
skin, 8 week isotretinoin treatment
|
male, 14, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298384 | GPL571 |
|
Pat 8_skin_baseline
|
skin, no treatment
|
male, 15, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
GSM298385 | GPL571 |
|
Pat 8_skin_treated
|
skin, 8 week isotretinoin treatment
|
male, 15, Caucasian
|
Subjects included males and females ages 14 to 40 years who were scheduled by their dermatologist to receive treatment with 13-cis RA (isotretinoin, brand not noted) for severe acne. All aspects of the patients’ treatment with 13-cis RA apart from the skin biopsies were standard of care and were not part of this research. Exclusion criteria included patients with underlying medical conditions requiring treatment with systemic medications that might interfere with the gene array analysis.
|
|
|
| |
| |
Make groups for comparisons |
(2 groups will be compared at a time) |
|
| Select GSMs and click on "Add groups" |
Enter the group name here: |
|
|
|
